Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? We have already applied this approach to several important tumour targets where enhancements in TCR-T therapy may lead to important gains in clinical benefit, including mutated KRAS, NY-ESO, and HPV E7 antigens.

Immune Response 105

Immune Response Therapies Vaccine Small Molecule 105

Drug Target Review

DECEMBER 13, 2024

1 Lung cancer is primarily classified into two types based on histological examination: Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). These types differ in their etiology, natural history, and present distinct challenges in disease management. percent of total cancer fatalities.

Therapies 52

Therapies Treatment Clinical Trials Drugs 52

Drug Target Review

DECEMBER 4, 2024

Confo Therapeutics , led by CEO Dr Cedric Ververken, is at the forefront of developing innovative GPCR-targeted therapies using its proprietary ConfoBody ® platform. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules.

Pharmacokinetics 78

Pharmacokinetics Small Molecule Therapies Engineering 78

The Pharma Data

JANUARY 5, 2021

(Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. The presentation will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. An archived replay of the webcast will be available for at least 30 days following the presentation. About Relay Therapeutics.

Small Molecule 40

Small Molecule Therapies Drugs 40

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Broad Institute

JUNE 30, 2023

The researchers also looked at the tool’s ability to detect changes in cellular phenotypes after exposure to drugs and small molecule compounds. Typically, studying drug therapies is an expensive and time-consuming undertaking.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

The Pharma Data

APRIL 11, 2023

Bayer is advancing its oncology R&D efforts in three scientific areas that have the potential to address unmet needs in cancer patients: next-generation Immuno-Oncology, Targeted Radionuclide Therapies and Precision Molecular Oncology. Data from all three areas of scientific focus will be showcased during this year’s meeting.

Research 40

Research Clinical Trials Small Molecule Trials 40

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Creative Biolabs

JUNE 29, 2023

At present, a large number of G protein-coupled receptor-targeted drugs have been marketed, and a large number of drugs are under development. While the development of small molecule drugs targeting GPCRs, the development of monoclonal antibody drugs has also received great attention.

Therapies 52

Therapies Small Molecule Drugs Drug Development 52

Drug Target Review

JULY 7, 2023

There is a clear need for new and approved, safe, effective and innovative targeted therapies to address the underlying causes of autoantibody diseases. The power of precision therapy Targeted — or precision — therapy, a technique that has been honed for many years in cancer treatment, is now being applied in a wider context.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

SEPTEMBER 28, 2020

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect. Research drawn from an animal-based clinical study led by Public Health England demonstrated the spray generated a reduction of up to 96% in viral replication of the novel coronavirus.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

LifeSciVC

JANUARY 3, 2024

Recognizing the therapeutic potential of effectively disrupting the CBM complex in the NF-kB pathway, using our technology, we have developed small molecules that we believe to be the first and only inhibitors of MALT1’s scaffolding function.

Drug Development 89

Drug Development Drugs Small Molecule Disease 89

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. An example is the collaboration between Novartis and the University of Oxford to develop a gene therapy for spinal muscular atrophy, a rare genetic disease.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

The Pharma Data

DECEMBER 5, 2020

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. The new data presented today strengthen our conviction that SY-1425 has the potential to become the foundation of care for all RARA-positive patients,” said David A.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

The Pharma Data

NOVEMBER 11, 2020

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. “As About SLV213.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

JANUARY 10, 2021

IDE397 program update to be presented at the 39th Annual J.P. “The IDE397 IND submission is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-in-class therapies. IDEAYA’s presentation for the 39 th Annual J.P. SOUTH SAN FRANCISCO, Calif. ,

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

JANUARY 13, 2021

Knopp expects to present results of the trial at a forthcoming medical meeting. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. The trial was conducted at 28 U.S. study centers. Please visit www.knoppbio.com. ABOUT ORAL DEXPRAMIPEXOLE.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative diseases and have the chance to improve the lives of millions of patients drastically.”.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

JANUARY 31, 2021

Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, and foreign patents.

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

Drug Target Review

JULY 12, 2023

We also leverage existing clinical gene expression data from different subsets of molecularly profiled cancer patients, who differ in a certain aspect of disease or response to a particular therapy. With this drop off, the goal is to reach a near-zero drug trough before the 24-hour mark.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

The Pharma Data

MAY 16, 2022

AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually. “We are proud to present data on a range of digestive conditions across our portfolio and pipeline. .

Disease 40

Disease Small Molecule Treatment Trials 40

The Pharma Data

MARCH 23, 2022

“These positive results demonstrate that etrasimod, if approved, could be a potential breakthrough option for patients with ulcerative colitis who aren’t able to experience improvement on current therapies,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.

Trials 52

Trials Small Molecule Biosimilars Therapies 52

The Pharma Data

JANUARY 19, 2021

This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers. CLARKSVILLE, Md., 20, 2021 (GLOBE NEWSWIRE) — Neuronascent Inc. , There is a great need for a disease-modifying treatment for the 5.3

Disease 40

Disease Small Molecule Clinical Trials Therapies 40

The Pharma Data

JANUARY 10, 2021

Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. At present, Chiauranib has globally applied for more than 40 patents of invention. About CHIPSCREEN BIOSCIENCES.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

LifeSciVC

APRIL 2, 2024

The science presents an opportunity and a challenge for us at Sionna. We are confident that there is room for improvement over existing cystic fibrosis (CF) therapies because we have not yet achieved fully normalized function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Science 65

Science Small Molecule International Clinical Development 65

Broad Institute

JUNE 21, 2023

The researchers also looked at the tool’s ability to detect changes in cell morphology after exposure to drugs and small molecule compounds. Typically, studying drug therapies is an expensive and time-consuming undertaking.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

LifeSciVC

DECEMBER 6, 2022

Darnell’s 2002 paper Transcription Factors as Targets for Cancer Therapy , in which he wrote: “A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. We are rapidly advancing the chemistry required modulate its activity.

Small Molecule 40

Small Molecule DNA Regulations Science 40

LifeSciVC

MARCH 1, 2023

Importantly, they also pointed to something that we at HotSpot Therapeutics and a small group of other researchers and companies recognized several years ago – that scientific advances have made this attractive, but once considered ‘undruggable,’ target druggable.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

KIF1A

MAY 27, 2023

Kaur in 2021, which she has leveraged into a 3-year federal grant; she now oversees 5 KAND research projects that utilize our patient-derived cell lines to screen for small molecule therapeutics and test potential gene therapies. So what’s different between these closely related proteins?

Science 94

Science Small Molecule Disease Research 94

The Pharma Data

OCTOBER 25, 2020

Astellas Pharma , FibroGen and AstraZeneca presented 42 abstracts about Roxadustat at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress. The FibroGen and AstraZeneca presentations focus on efficacy and safety data from pooled analyses from several Phase III trial of patients on and not on dialysis.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Alta Sciences

APRIL 17, 2024

Psychedelics Psychedelic therapy (or psychedelic-assisted therapy) refers to the use of psychedelic drugs, such as psilocybin, MDMA, LSD, ketamine, and ayahuasca, to treat mental disorders, especially those that have no effective treatments available or are treatment resistant.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

The Pharma Data

AUGUST 30, 2021

The head-to-head study was designed to directly compare the efficacy of abrocitinib 200mg versus dupilumab 300mg, in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD). Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. About Abrocitinib.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

The Pharma Data

NOVEMBER 23, 2020

His most recent position was at Amgen as Director Global Business Development – Transactions, a position he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule development company, at which he led the commercial and business activities as Chief Business Officer.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Advarra

FEBRUARY 24, 2023

How do you know your experimental therapy is working? How do you strategically plan your therapy and research objectives to improve the chances you will satisfy what the regulators are looking for and ultimately get your therapy approved for marketing?

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

The Pharma Data

DECEMBER 20, 2020

The therapy is a combination of anticoagulant, anti-inflammatory and antiviral effects. Auxora is a potent and selective small molecule CRAC channel inhibitor that prevents CRAC channel overactivation. FLT180a is an AAV gene therapy. The product is an AAV9-based gene therapy for GM1 gangliosidosis.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

MARCH 18, 2022

They control the iCAP system by giving it an external cue – a small molecule called IPTG – that allows for programmable and dynamic alteration of the E. Using Bacteria For Therapy. The cloaking approach presented in this study may address this critical issue.” .” An Effective On/Off Switch.

Engineering 52

Engineering Drugs Small Molecule Therapies 52

New Drug Approvals

JANUARY 31, 2024

It works as a colony-stimulating factor 1 ( CSF1 ) receptor inhibitor. [1] It works as a colony-stimulating factor 1 ( CSF1 ) receptor inhibitor. [1]

Small Molecule 52

Small Molecule Virus Treatment Disease 52